T. Rowe Price Associates’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

T. Rowe Price Associates’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,427	Closed	-$225K	–	3017
2022 Q3	$225K	Hold	22,427	–	–	﹤0.01%	2499
2022 Q2	$222K	Hold	22,427	–	–	﹤0.01%	2562
2022 Q1	$221K	Hold	22,427	–	–	﹤0.01%	2678
2021 Q4	$219K	Buy	22,427 +2,127	+10%	+$20.8K	﹤0.01%	2724
2021 Q3	$199K	Hold	20,300	–	–	﹤0.01%	2729
2021 Q2	$200K	Buy	+20,300	New	+$200K	﹤0.01%	2733

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

T. Rowe Price Associates's EUCR Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 22,427 shares — an estimated $225K sold.

T. Rowe Price Associates first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $225K in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

T. Rowe Price Associates reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
T. Rowe Price Associates sold 22,427 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $225K.
T. Rowe Price Associates first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
T. Rowe Price Associates's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $225K in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.